Tezacitabine and Oxaliplatin for the Treatment of Patients With Metastatic Colorectal Cancer

This study has been terminated.

Sponsored by:	Chiron Corporation
Information provided by:	Chiron Corporation
ClinicalTrials.gov Identifier:	NCT00051688

Purpose

The primary purpose of this study is to determine the best dose of tezacitabine when combined with oxaliplatin in patients with metastatic colorectal cancer. This study will also evaluate tumor response to the combination of anti-cancer drugs.

Condition	Intervention	Phase
Colorectal Neoplasms	Drug: tezacitabine Drug: oxaliplatin	Phase II

MedlinePlus related topics: Cancer Colorectal Cancer

Drug Information available for: Oxaliplatin MDL 101731 Tezacitabine

U.S. FDA Resources

Study Type:	Interventional
Study Design:	Treatment

Further study details as provided by Chiron Corporation:

Study Start Date:	June 2003
Estimated Study Completion Date:	August 2004

Eligibility

Ages Eligible for Study:	18 Years and older
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

Patients with metastatic colorectal adenocarcinoma who have failed one prior course of chemotherapy.
Patients must have at least one measurable tumor.
Patients may not have received prior treatment with oxaliplatin.

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00051688

Locations

United States, Arizona
ACRC/Arizona Clinical Research Center
Tucson, Arizona, United States, 85712
United States, California
Cancer Institute Medical Group
Santa Monica, California, United States, 90404
USC/Norris Comprehensive Cancer Center
Los Angeles, California, United States, 90033
Comprehensive Cancer Centers of the Desert
Palm Springs, California, United States, 92262
United States, District of Columbia
Georgetown University Medical Center, Lombardi Cancer Center
Washington, District of Columbia, United States, 20007
United States, Florida
H. Lee Moffitt Cancer Center & Research Institute
Tampa, Florida, United States, 33612-9497
United States, Illinois
Northwestern University Feinberg School of Medicine
Chicago, Illinois, United States, 60611
United States, Missouri
Kansas City Oncology and Hematology Group
Kansas City, Missouri, United States, 64111

Sponsors and Collaborators

Chiron Corporation

More Information

Study ID Numbers:	TEZ101
Study First Received:	January 15, 2003
Last Updated:	July 10, 2006
ClinicalTrials.gov Identifier:	NCT00051688
Health Authority:	United States: Food and Drug Administration

Study placed in the following topic categories:

Oxaliplatin
Digestive System Diseases
Digestive System Neoplasms
Gastrointestinal Diseases
Colonic Diseases
2'-deoxy-2'-(fluoromethylene)cytidine

Gastrointestinal Neoplasms
Intestinal Diseases
Rectal Diseases
Intestinal Neoplasms
Colorectal Neoplasms

Additional relevant MeSH terms:

Neoplasms
Neoplasms by Site
Radiation-Sensitizing Agents
Molecular Mechanisms of Pharmacological Action
Antineoplastic Agents

Therapeutic Uses
Physiological Effects of Drugs
Enzyme Inhibitors
Pharmacologic Actions

ClinicalTrials.gov processed this record on January 15, 2009